Rajkumar Venkatramani1, Jeffrey Murray2, Lee Helman3, William Meyer4, M John Hicks5, Robert Krance1, Ching Lau1, Eunji Jo6, Murali Chintagumpala1. 1. Department of Pediatrics, Baylor College of Medicine, Texas Children's Cancer Center, Texas Children's Hospital, Houston, Texas. 2. Cook Children's Medical Center, Fort Worth, Texas. 3. National Institutes of Health Clinical Center, Pediatric Oncology Branch, Bethesda, Maryland. 4. Department of Pediatrics, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma. 5. Department of Pathology and Immunology and Department of Pediatrics, Baylor College of Medicine, Houston, Texas. 6. Biostatistics and Informatics Shared Resource, The Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.
Abstract
BACKGROUND: The outcome of localized osteosarcoma has remained constant over the past 30 years. Histological response to preoperative chemotherapy is the best predictor of outcome. Strategies to alter treatment based on histological response have not resulted in increased survival. PROCEDURE: Patients with localized osteosarcoma received preoperative chemotherapy with cisplatin, doxorubicin, and methotrexate. Patients whose tumors had a good histological response (≥90% necrosis) continued with the same treatment postoperatively. Patients with poor histological response (<90% necrosis) received three courses of melphalan 100 mg/m(2) on day -4, cyclophosphamide 2,000 mg/m(2) on days -3, and -2 followed by stem cell infusion. RESULTS: Fifty-two patients were enrolled. Median age was 14 years, and 56% of patients were male. The femur was the most common site. Forty patients underwent limb salvage surgery and amputation was performed in six patients. Forty-eight percent of tumors showed good histological response. Forty patients were evaluable for outcome; 18 patients with poor histologic response received high-dose chemotherapy. The 5-year event-free survival (EFS) and overall survival (OS) for patients treated on the high-dose chemotherapy arm were 28% (95% confidence interval [CI], 10-49) and 48% (95% CI, 23-69), respectively. The 5-year EFS and OS for patients treated on the standard chemotherapy arm were 62% (95% CI, 36-80) and 74% (95% CI, 44-90), respectively. All patients who received high-dose chemotherapy developed grade 3 or higher hematological toxicity. There were no treatment-related deaths. CONCLUSIONS: Postoperative alkylator intensification with high-dose cyclophosphamide and melphalan in patients with localized osteosarcoma with poor histological response failed to improve survival.
BACKGROUND: The outcome of localized osteosarcoma has remained constant over the past 30 years. Histological response to preoperative chemotherapy is the best predictor of outcome. Strategies to alter treatment based on histological response have not resulted in increased survival. PROCEDURE: Patients with localized osteosarcoma received preoperative chemotherapy with cisplatin, doxorubicin, and methotrexate. Patients whose tumors had a good histological response (≥90% necrosis) continued with the same treatment postoperatively. Patients with poor histological response (<90% necrosis) received three courses of melphalan 100 mg/m(2) on day -4, cyclophosphamide 2,000 mg/m(2) on days -3, and -2 followed by stem cell infusion. RESULTS: Fifty-two patients were enrolled. Median age was 14 years, and 56% of patients were male. The femur was the most common site. Forty patients underwent limb salvage surgery and amputation was performed in six patients. Forty-eight percent of tumors showed good histological response. Forty patients were evaluable for outcome; 18 patients with poor histologic response received high-dose chemotherapy. The 5-year event-free survival (EFS) and overall survival (OS) for patients treated on the high-dose chemotherapy arm were 28% (95% confidence interval [CI], 10-49) and 48% (95% CI, 23-69), respectively. The 5-year EFS and OS for patients treated on the standard chemotherapy arm were 62% (95% CI, 36-80) and 74% (95% CI, 44-90), respectively. All patients who received high-dose chemotherapy developed grade 3 or higher hematological toxicity. There were no treatment-related deaths. CONCLUSIONS: Postoperative alkylator intensification with high-dose cyclophosphamide and melphalan in patients with localized osteosarcoma with poor histological response failed to improve survival.
Authors: D Andreou; S S Bielack; D Carrle; M Kevric; R Kotz; W Winkelmann; G Jundt; M Werner; S Fehlberg; L Kager; T Kühne; S Lang; M Dominkus; G U Exner; J Hardes; A Hillmann; V Ewerbeck; U Heise; P Reichardt; P-U Tunn Journal: Ann Oncol Date: 2010-10-28 Impact factor: 32.976
Authors: K Winkler; G Beron; G Delling; U Heise; H Kabisch; C Purfürst; J Berger; J Ritter; H Jürgens; V Gerein Journal: J Clin Oncol Date: 1988-02 Impact factor: 44.544
Authors: M L Graham; J E Herndon; J R Casey; S Chaffee; G H Ciocci; J P Krischer; J Kurtzberg; M J Laughlin; D C Longee; J F Olson; N Paleologus; C N Pennington; H S Friedman Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: A J Provisor; L J Ettinger; J B Nachman; M D Krailo; J T Makley; E J Yunis; A G Huvos; D L Betcher; E S Baum; C T Kisker; J S Miser Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544
Authors: N Baldini; K Scotlandi; G Barbanti-Bròdano; M C Manara; D Maurici; G Bacci; F Bertoni; P Picci; S Sottili; M Campanacci Journal: N Engl J Med Date: 1995-11-23 Impact factor: 91.245
Authors: Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban Journal: Cancer Date: 1982-03-15 Impact factor: 6.860